These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 8960658)
1. [Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leukemic blasts]. Hagiwara S; Yuo A; Nagai M; Takezako N; Soda Y; Miwa A; Togawa A; Takaku F Rinsho Ketsueki; 1996 Nov; 37(11):1259-64. PubMed ID: 8960658 [TBL] [Abstract][Full Text] [Related]
2. [In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia]. Takeyama H; Kajiguchi T; Miyata Y; Saito M Gan To Kagaku Ryoho; 2000 Jun; 27(6):873-8. PubMed ID: 10897214 [TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Cannistra SA; Groshek P; Griffin JD Leukemia; 1989 May; 3(5):328-34. PubMed ID: 2654494 [TBL] [Abstract][Full Text] [Related]
4. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study. Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057 [TBL] [Abstract][Full Text] [Related]
5. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970 [TBL] [Abstract][Full Text] [Related]
6. Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia. Asano Y; Yokoyama T; Shibata S; Kobayashi S; Shimoda K; Nakashima H; Okamura S; Niho Y Cancer Res; 1997 Aug; 57(16):3395-7. PubMed ID: 9270003 [TBL] [Abstract][Full Text] [Related]
7. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031 [TBL] [Abstract][Full Text] [Related]
8. [Hypoplastic leukemia which achieved remission with administration of M-CSF along with low dose ara-C]. Kamimura N; Nakamura T Rinsho Ketsueki; 1993 May; 34(5):662-6. PubMed ID: 8315838 [TBL] [Abstract][Full Text] [Related]
9. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation]. Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721 [TBL] [Abstract][Full Text] [Related]
11. CSFs in combination with cytosine arabinoside, an inhibitor of DNA synthesis: potential strategies for the treatment of myeloid disorders. Brach M; Stone R; Kufe D Biotechnol Ther; 1991; 2(3-4):269-83. PubMed ID: 1845130 [TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573 [TBL] [Abstract][Full Text] [Related]
13. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Gandhi V; Estey E; Du M; Keating MJ; Plunkett W Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841 [TBL] [Abstract][Full Text] [Related]
14. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes. Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864 [No Abstract] [Full Text] [Related]
15. Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside. Yang GS; Wang C; Minkin S; Minden MD; McCulloch EA J Cell Physiol; 1991 Jul; 148(1):60-7. PubMed ID: 1860896 [TBL] [Abstract][Full Text] [Related]
16. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. Winer ES; Miller KB; Chan GW Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):11-4. PubMed ID: 15934494 [TBL] [Abstract][Full Text] [Related]
17. Sequential promotion of normal and leukemic hemopoiesis by recombinant human granulocyte colony-stimulating factor during the course of myelodysplastic syndrome. Ueda T; Kawai Y; Sugiyama T; Takeuchi N; Yoshida A; Iwasaki H; Wano Y; Tsutani H; Kamada N; Nakamura T Int J Hematol; 1993 Dec; 59(1):47-52. PubMed ID: 7512833 [TBL] [Abstract][Full Text] [Related]
18. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A; Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637 [TBL] [Abstract][Full Text] [Related]
19. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. Andreeff M; Tafuri A; Hegewisch-Becker S Haematol Blood Transfus; 1990; 33():747-62. PubMed ID: 2323674 [TBL] [Abstract][Full Text] [Related]
20. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Hubeek I; Litvinova E; Peters GJ; Broekhuizen R; Haarman EG; Huismans DR; Cloos J; Zwaan CM; Fleischhack G; Creutzig U; Kaspers GJ Int J Oncol; 2004 Dec; 25(6):1823-9. PubMed ID: 15547723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]